• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Friday, May 30
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

    May 29, 2025

    ‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

    May 29, 2025

    DeSantis Signs Bill Making Gold And Silver Legal Tender

    May 28, 2025

    John Deere Announces $20 Billion Plan To Build Up American Manufacturing

    May 28, 2025

    EV Startup Promised To Cut China Ties — Then Reportedly Shared US Data Anyway

    May 27, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Business»Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
Business

Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data

February 13, 2023No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Feb 13 (Reuters) – Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors more inclined to pick firms which have drugs in human trials.

Globally, IPOs across all sectors nosedived last year after a blockbuster 2021, as aggressive interest rate hikes by central banks to curb inflation put an end to the era of cheap money.

In the biotech sector, there were only 47 IPOs last year that raised a total of about $4 billion, compared with 152 offerings in 2021 that had raised over $25 billion.

However, more biotech companies are expected to tap the U.S. IPO market this year as the Federal Reserve dials down the size of its rate hikes and private investment rounds fail to raise adequate capital to fund expensive clinical trials, industry experts told Reuters.

Latest Updates

View 2 more stories

Still, companies that have not yet tested their drugs on humans may find it hard to attract equity investors’ attention given tighter financial conditions and a slew of disappointments from preclinical companies that went public during the IPO boom of 2021.

“The pattern of the past few years has been to come to the market with almost anything, no matter how substantial the validation,” said David Pinniger, fund manager of the Biotech fund at Polar Capital.

“In these more discerning days, the weight of clinical evidence is probably going to have to be that much greater,” Pinniger added.

See also  Inflation Eased More Than Expected In April, Slowing To Lowest Level Since 2021

Several preclinical-stage biotechs that went public in 2021 are now trading well below their IPO price, including Sana Biotechnology (SANA.O), Tenaya Therapeutics (TNYA.O) and Virpax Pharmaceuticals (VRPX.O).

Reuters Graphics

Along with challenging macro conditions, a string of disappointing clinical data and a dearth of large acquisitions had also sapped investor interest in the biotech sector in the first half of 2022, hammering company valuations.

Small drug developers without any approved products on the market were forced to cut costs by dropping some drug study programs and implementing layoffs as funding dried up.

Sentiment started to rebound late in 2022 and has continued into this year, with the SPDR S&P Biotech ETF , considered a yardstick for the performance of small-cap biotech firms, having risen about 3% so far this year after posting its biggest annual loss last year.

While the XBI is still trading 50% below its February 2021 closing high, analysts believe the downturn in biotech has bottomed out. They also believe the outlook for the rest of the year is much brighter given the likelihood of multi-billion dollar acquisitions and innovations such as genome editing and targeted cancer drug developments.

Biopharma companies held more than $1.4 trillion in dealmaking capacity at the beginning of December 2022, according to a report by EY, with pharmaceutical giants facing patent expiries for their key drugs on the hunt for new promising assets.

“There was this dam holding back all this capital,” said Sean Sun, portfolio manager at Thornburg Investment Management.

“Now we’re in this sweet spot where you’re seeing signs of disinflation, you’re seeing risk appetite improve. All we need is one or two biotech IPOs to get good interest and the floodgates will open.”

See also  Healthcare companies counter investor worries over Wegovy effect

Analysts have pointed to developmental obesity treatments, Alzheimer’s disease drugs, cell and gene therapies, and the breakthrough messenger-RNA technology among areas attracting investor interest.

Reuters Graphics

The second half of 2023 is more likely to see a significant step-up in biotech IPOs instead of the first half, as markets await further clarity on potential rate cuts, analysts said.

Along with robust clinical data, investors will be looking for companies with management teams that are capable of steering them to success after their stock market listings.

“A silver lining in the biotech downturn is that companies realize that they’re not necessarily entitled to great valuations because they have some interesting science,” SMBC Nikko Securities America analyst David Hoang said.

“The way private companies are messaging their story and thinking about pushing their pipelines forward has improved compared to the last two years,” Hoang added.

A few biotech firms have already filed for an IPO this year, with clinical-stage drug developers Mineralys Therapeutics (MLYS.O) and Structure Therapeutics (GPCR.O) having successful market debuts following their offerings.

Reporting by Amruta Khandekar and Bhanvi Satija; Editing by Alden Bentley

: .

Analysis Biotech bloom data human IPOs Spotlight startups trial
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025

John Deere Announces $20 Billion Plan To Build Up American Manufacturing

May 28, 2025
Add A Comment

Leave A Reply Cancel Reply

Top Posts

EXCLUSIVE: Second-Largest Foreign Owner Of US Land Is A Chinese Communist Party Member

January 11, 2024

How to Change Your Life in Just 2 Minutes a Day: 10 Quick Habits

December 13, 2023

Tennessee coach accused of recording himself raping drugged boys is also an illegal alien, officials say

July 13, 2023

Disney in talks with Adani, Sun TV to sell India assets, Bloomberg reports

October 6, 2023
Don't Miss

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

Business May 29, 2025

Consumers’ Research issued a “Woke Alert” on Thursday warning American shoppers that three European companies…

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025

John Deere Announces $20 Billion Plan To Build Up American Manufacturing

May 28, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,136)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,645)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

‘Hypocritical’: NY counties declare states of emergency as NYC mayor threatens to bus migrants to suburbs

May 10, 2023

Saturday Night Live April Fool’s Prank: Michael Che Tricks Colin Jost

April 2, 2023

Sanders supporters took over the Nevada Democratic Party. It’s not going well.

February 25, 2023
Popular Posts

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.